Ingredient for protecting the skin and / or mucous membranes from virulence factors

EP4469019A1Pending Publication Date: 2024-12-04BASF BEAUTY CARE SOLUTIONS FRANCE SAS
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
EP2023706401
Authority / Receiving Office
EP · EP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-01-25
Filing Date
2023-01-24
Publication Date
2024-12-04

AI Technical Summary

Technical Problem

Current cosmetic and dermatological solutions fail to effectively target Cutibacterium acnes, leading to unsightly and uncomfortable manifestations like acne, as they are not specifically directed against this microbial strain, and antibiotics have drawbacks such as resistance development and impact on commensal flora.

Method used

A combination of pullulan, hyaluronic acid, alginic acid, lactic acid, succinic acid, and sucrose, which inhibits the adhesion and biofilm production of Cutibacterium acnes, reducing its virulence and associated skin issues.

Benefits of technology

The combination significantly reduces the virulence of Cutibacterium acnes by inhibiting biofilm formation and adhesion, providing a targeted and effective solution without the drawbacks of existing treatments, as demonstrated by synergistic effects in reducing biofilm formation and adhesion.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000038_0001
    Figure IMGF000038_0001
  • Figure IMGF000039_0001
    Figure IMGF000039_0001
  • Figure IMGF000039_0002
    Figure IMGF000039_0002
Patent Text Reader

Abstract

The present invention relates to a new combination comprising: pullulan or one of its derivatives; a polysaccharide selected from hyaluronic acid or one of its salts or derivatives; alginic acid or one of its salts or derivatives or a mixture thereof; succinic acid or one of its salts or derivatives; lactic acid or one of its salts or derivatives; and sucrose or one of its salts or derivatives, this combination being particularly useful for preventing and / or reducing the virulence of C. acnes.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] SKIN AND / OR MUCOUS MEMBRANES PROTECTIVE INGREDIENT

[0002] AGAINST VIRULENCE FACTORS

[0003] Technical Field

[0004] The present invention relates to the field of cosmetics and the pharmaceutical field, in particular dermatology. The present invention relates in particular to a new combination of pullulan and / or its derivatives in association with

[0005] - on the one hand a polysaccharide chosen from the group consisting of hyaluronic acid, one of its salts or derivatives, alginic acid, one of its salts or derivatives and a mixture of these and

[0006] - on the other hand lactic acid, one of its salts or derivatives, succinic acid, one of its salts or derivatives and sucrose, one of its salts or derivatives.

[0007] This new combination is composed of a mixture of compounds having a synergistic action allowing to limit and / or reduce the virulence of Cutibacterium acnes, in particular the formation of the biofilm and thus prevent and / or reduce the uncomfortable and / or unpleasant and / or unsightly manifestations of the virulence factors of Cutibacterium acnes. It also allows to treat pathologies associated with / due to the virulence of C. acnes, in particular to the virulence factors of Cutibacterium acnes, such as acne.

[0008] Prior art

[0009] The skin is the largest organ in the human body. It plays a major role in protecting against external aggressions such as environmental aggressions, climatic aggressions, pollution, allergens and pathogenic germs. The skin also represents a complex ecosystem on which several types of microorganisms such as bacteria and fungi proliferate. These microorganisms constitute the skin flora, also called cutaneous microbial flora. A distinction is made between resident or commensal flora such as Propionibacterium acnes, also called Cutibacterium acnes, which normally lives on the skin. Under certain conditions, certain strains of C. acnes can become more virulent and therefore cause pathologies.

[0010] Cutibacterium acnes, when it expresses virulence factors, can in fact cause unsightly and / or unpleasant and / or uncomfortable manifestations such as redness, swelling or even spots and a sensation of burning and / or localized heat accompanied by pain, pigment spots or scars, for example following acne and therefore uneven skin tone. It can also contribute to real skin pathologies such as acne. The alteration caused at the level of the skin barrier by C. acnes can also contribute to real opportunistic infections by other bacteria and / or mycoses such as candidiasis. Cosmetic or dermatological solutions are already known to act on bacteria, for example antiseptics. However, their modes of action are not targeted because they are not directed against a specific strain of microorganism.Antibiotics are then a solution allowing to act on a targeted group of the cutaneous microbial flora but these have the disadvantages of not always being tolerated, of inducing the development of resistance and of acting on the commensal microbial flora, which can also result in the appearance of mycoses. Consequently, there is a significant need in the field of cosmetics and dermatology to provide alternative active ingredients with a targeted action on a particular microbial strain, which are easily available and do not have the disadvantages or side effects previously described.

[0011] Unexpectedly, the inventors discovered that a combination comprising:

[0012] - pullulan and / or one of its derivatives - a polysaccharide chosen from the group consisting of hyaluronic acid, one of its salts or derivatives, alginic acid, one of its salts or derivatives, and a mixture thereof

[0013] - lactic acid, one of its salts or derivatives

[0014] - succinic acid, one of its salts or derivatives and

[0015] - sucrose, one of its salts or derivatives had the capacity to limit and / or reduce the virulence of Cutibacterium acnes strains, in particular by at least one of the following mechanisms:

[0016] - by inhibiting or limiting the adhesion of Cutibacterium acnes strains;

[0017] - by inhibiting or limiting the production of virulence factors of Cutibacterium acnes strains, such as biofilm.

[0018] The mixture of a pullulan with another polysaccharide chosen from hyaluronic acid and alginic acid and their mixtures, optionally in the form of their respective salts or derivatives has already been described by the Applicant in a previous patent application published under number WO2014027163A2 for its properties of:

[0019] - reduction of insensible water losses,

[0020] - maintaining the water content of the skin and / or mucous membranes,

[0021] - increased water content of the skin and / or mucous membranes, and

[0022] - increasing and / or prolonging the content of cosmetic and / or pharmaceutical active ingredients in the skin and / or mucous membranes.

[0023] This same mixture has also already been described by the Applicant in a previous patent application published under number FR3064473A1 for its properties of maintaining the balance of the bacterial flora of the skin and / or mucous membranes.

[0024] Sucrose has also been described as promoting the specific fermentation of S. epidermidis, which will produce succinic acid, a compound that belongs to the family of short-chain fatty acids (SCFAs) and described in the literature as inhibiting the growth of C. acnes.

[0025] Particularly surprisingly, the inventors discovered that the new combination according to the invention exhibited synergistic effects against the virulence factors of C. acnes. The effect of the combination according to the invention on the formation of the C. acnes biofilm is in fact superior to the effect obtained on the one hand with the mixture described in the previous patent application published under number FR3064473A1 and on the other hand superior to that obtained with a mixture of sucrose, lactic acid and succinic acid. This synergistic action of the compounds of the new combination according to the invention is demonstrated in Example 2. Technical problem

[0026] The inventors thus discovered that the combination according to the invention addressed the technical problem previously stated without the drawbacks of the prior art in a particularly unexpected manner.

[0027] Statement of the invention

[0028] The present invention therefore relates to a combination comprising:

[0029] - pullulan or one of its derivatives, and

[0030] - a polysaccharide chosen from the group consisting of hyaluronic acid, one of its salts or derivatives, alginic acid, one of its salts or derivatives, and mixtures thereof, and

[0031] - lactic acid, one of its salts or derivatives, and

[0032] - succinic acid, one of its salts or derivatives and

[0033] - sucrose, one of its salts or derivatives.

[0034] The combination may be in the form of a mixture of the compounds listed above and consist only of these compounds, or may be in the form of a mixture of cosmetic or pharmaceutical ingredients, in particular dermatological ingredients, for example when the combination is combined with xanthan gum and / or glycerin and / or pentylene glycol and / or caprylyl glycol and / or water, advantageously xanthan gum and / or glycerin. The combination may alternatively be in the form of a cosmetic or pharmaceutical composition, in particular a dermatological composition. The present invention also relates to the cosmetic use of this combination or of the mixture of cosmetic ingredients or of a cosmetic composition comprising the combination according to the invention for limiting and / or reducing the virulence of Cutibacterium acnes strains on the skin and / or mucous membranes, in particular by at least one of the following mechanisms:

[0035] - by inhibiting or limiting the adhesion of Cutibacterium denes,'

[0036] - by inhibiting or limiting the production of virulence factors of Cutibacterium acnes such as biofilm.

[0037] The present invention also relates to the cosmetic use of the combination according to the invention to prevent and / or reduce unsightly and / or unpleasant and / or uncomfortable manifestations due to the virulence of C. acnes.

[0038] The present invention also relates to the combination according to the invention, or the mixture of pharmaceutical ingredients according to the invention or the pharmaceutical composition, in particular dermatological, according to the invention for its use as a pharmaceutical active ingredient, in particular dermatological, in particular for preventing and / or treating pathologies due to the virulence of C. acnes, advantageously involving an increase in the secretion of biofilm by C. acnes and / or an increase in the adhesion of C. acnes.

[0039] Generally speaking, the virulence factors of C. acnes can be responsible for unsightly and / or unpleasant and / or uncomfortable manifestations which are not diseases but which we wish to avoid for aesthetic and / or comfort reasons such as:

[0040] - increased production of sebum and / or a change in its quality which results in shiny skin, a loss of skin radiance, a so-called "dull" or less luminous complexion, causes the appearance of blackheads, an increase in the size of skin pores and / or comedogenesis (appearance of spots), spots which can subsequently leave spots and / or scars and / or

[0041] - an imperfection of the skin tone (redness and / or irregularities and / or pigment spots and / or scars) and therefore unevenness of the complexion and / or

[0042] - a feeling of warming and / or

[0043] - hair loss and / or hair loss and / or

[0044] - the appearance of dandruff.

[0045] The virulence factors of C. acnes can also contribute, in the most severe cases and under multifactorial conditions, to the appearance of pathologies of the skin and / or mucous membranes, such as bacterial infections of the skin and / or mucous membranes, pustules, papules, boils, folliculitis, abscesses, and / or acne, especially superinfected, and / or delayed wound healing and even their superinfection and / or inflammation of the skin and / or mucous membranes. They can also contribute to the appearance of scar marks on the skin in the form of pigment spots and / or acne scars.

[0046] In particular, the area of ​​skin on which the treatment using the combination according to the invention, optionally in the form of a mixture of cosmetic or pharmaceutical ingredients or a cosmetic or pharmaceutical composition, is particularly useful, is the area of ​​skin or mucous membrane having a large quantity of cutaneous and / or mucosal C. acnes such as the face, in particular the neck, chin, nose, forehead, cheeks, shoulders, arms, back, torso; and / or the area of ​​skin or mucous membrane whose skin barrier has been altered, for example, due to a mechanical, chemical or biological action, such as sunburn (solar erythema), the action of a razor, the use of unsuitable or overly astringent cleaning products, pollution, the use of antibiotics, allergens, etc.

[0047] These may include irritated areas, weakened areas, shaved areas, inflamed areas, scars and / or wounds.

[0048] The combination according to the invention comprises pullulan and a polysaccharide chosen from alginic acid and / or hyaluronic acid, their salts and / or derivatives. Advantageously, the polysaccharide is propylene glycol alginate, sodium hyaluronate and / or their mixtures.

[0049] Pullulan is a natural polysaccharide (polymer of sugar) consisting of maltotriose units (a glucose trisaccharide), also known as α-1,4-α1,6-glucan. The three glucose units that make up maltotriose are linked by an α-1,4-saccharide bond, while the maltotrioses are connected to each other by α-1,6-saccharide bonds. Pullulan is produced from starch by the fungus Aureobasidium pullulans and can be obtained from various Aureobasidium pullulans ferments. According to the present invention, pullulan can be used in its aqueous form, optionally in saline form.The pullulan derivatives that can be used in the context of the present invention are cosmetically and / or pharmaceutically acceptable derivatives, preferably dermatologically acceptable, that is to say that they are non-toxic for administration to humans, in particular by topical application, and can be applied without risk and without causing an allergic or inflammatory reaction, in particular on the skin. In an advantageous embodiment, the pullulan derivatives are chosen from silicon-based organomineral derivatives commonly used in cosmetics, such as, for example, those chosen from trimethylsiloxysilylcarbamoyl pullulan and trimethylsilyl pullulan.

[0050] Advantageously in the combination, pullulan is not in derivative form. In particular, pullulan has a weight-average molecular weight, advantageously measured by size exclusion chromatography, of less than 500 kDa, advantageously about 200 kDa. Pullulan is commercially available (Chemaster International, China; Hayashibara, Japan).

[0051] Hyaluronic acid, its salts and derivatives are among the best known and most widely used moisturizing active ingredients today. Hyaluronic acid is a polymer of disaccharides, themselves composed of D-glucuronic acid and DN-acetylglucosamine, linked together by alternating beta-1,4 and beta-1,3 glycosidic bonds. It is therefore a natural glycosaminoglycan. It is one of the main components of the extracellular matrix. Its different fractions, depending on their molecular weights, can be used as a moisturizing agent as described in patent application US2008 / 0003271.

[0052] Alginic acid and its derivatives (conjugate base, salts and esters) are natural polysaccharides obtained from a family of brown algae: laminaria or fucus. Alginate is a polymer formed from two monomers linked together: mannuronate or mannuronic acid, some of which are acetylated, and guluronate or guluronic acid. The bond is via beta 1-4. Alginates are used as thickeners, gelling agents, emulsifiers and stabilizers for a wide variety of industrial products. They are also known to have water retention properties. Preferably, particularly when the combination, the mixture of cosmetic and / or pharmaceutical ingredients or the cosmetic or pharmaceutical composition according to the invention contains a lot of salts, the alginic acid will be in the form of propylene glycol alginate, to facilitate the formulation and use of the combination and the compositions containing it.

[0053] Particularly advantageously, pullulan is in association with alginic and / or hyaluronic acid as described in application WO2014027163. According to the invention, the “derivatives” are preferably esterified derivatives and organomineral derivatives based on silicon.

[0054] For the purposes of the present invention, the term "esterified derivatives of one of the compounds", in particular pullulan, hyaluronic acid, alginic acid, succinic acid, lactic acid or sucrose, means all the derivatives obtained by simple or multiple esterification of a primary or secondary alcohol function or of an acid function of the compound, and having on the esterified part a carbon chain comprising from 1 to 6 carbon atoms, advantageously a linear or branched alkyl chain.

[0055] For the purposes of the present invention, the term "organomineral derivatives based on silicon of pullulan, hyaluronic acid or alginic acid" means all derivatives which contain at least one silanol (-SiOH) and obtained by condensation of pullulan, hyaluronic acid or alginic acid with a molecule from the silane family.

[0056] For the purposes of the present invention, the term "acid salts", in particular of hyaluronic acid or alginic acid or lactic acid or succinic acid, means the ionic compounds which result from the neutralization reaction of the acid form by an anion, in particular inorganic, in particular chloride, sulfate, phosphate, sodium, potassium and magnesium.

[0057] The hyaluronic acid salts and derivatives that can be used in the context of the present invention are cosmetically and / or pharmaceutically acceptable salts or derivatives, preferably dermatologically acceptable. Advantageously, the hyaluronic acid salts are chosen from hydrolyzed calcium hyaluronate, hydrolyzed sodium hyaluronate, potassium hyaluronate, sodium hyaluronate, sodium sulfated hyaluronate and mixtures thereof. Advantageously, it is sodium hyaluronate.In an advantageous embodiment, the hyaluronic acid derivatives are chosen from derivatives commonly used in cosmetics such as, for example, those chosen from esterified derivatives, in particular ascorbyl hyaluronate, benzyl hyaluronate, propylene glycol hyaluronate, sodium acetylated hyaluronate, sodium butyroyl hyaluronate or hydroxypropyltrimonium hyaluronate, organomineral silicon derivatives, in particular dimethylsilanol hyaluronate and mixtures thereof.

[0058] Advantageously in the combination with pullulan or one of its derivatives according to the invention, hyaluronic acid is in the form of one of its salts. Advantageously, this is sodium hyaluronate. In particular, hyaluronic acid, its salts or esterified derivatives have a weight-average molecular weight, advantageously measured by size exclusion chromatography, greater than 20 kDa, advantageously between 50 and 800 kDa, advantageously between 250 and 450 kDa. Sodium hyaluronate is commercially available, in particular, from the companies Technidd Chemi-tech, Wuhan Fortuna Chemical, Dalian Chem lmp. and Exp. Group, Afine Chemicals Limited, Javenech SA, Soliance, Maprecos, Landy Enterprise Limited, Chandigarh Medical Corporation, Kartik Enterprises, DSA Exports.The salts and derivatives of alginic acid that can be used in the context of the present invention are cosmetically and / or pharmaceutically acceptable salts or derivatives, preferably dermatologically acceptable. Advantageously, the salts of alginic acid are chosen from ammonium alginate, sodium alginate, calcium alginate, magnesium alginate, sodium alginate sulfate and potassium alginate. Advantageously, it is sodium alginate. In an advantageous embodiment, the alginic acid derivatives are chosen from derivatives commonly used in cosmetics, such as, for example, those chosen from esterified derivatives, in particular glyceryl alginate or propylene glycol alginate, organomineral silicon derivatives of alginic acid, in particular siloxanetriol alginate or methylsilanol carboxymethyl theophylline alginate, and mixtures thereof.In particular, the derivative is propylene glycol alginate. Advantageously, in the combination with pullulan or one of its derivatives, according to the invention, the alginic acid is in the form of one of its salts. Advantageously, it is sodium alginate. Advantageously, the alginic acid, its salts or derivatives, in particular esterified or organomineral silicon, have a weight-average molecular weight, advantageously measured by size exclusion chromatography, of between 10 and 600 kDa, preferably between 30 and 550 kDa, more preferably from 100 to 550 kDa. Sodium alginate is commercially available, in particular, from the companies Laserson SA, Univar, Danisco Ingredients, BASF, BAM, Penta Manufacturing Company, Vevy Europe.

[0059] Advantageously, the alginic acid will be in the form of propylene glycol alginate or mixtures thereof.

[0060] In one embodiment of the present invention, the weight ratio of pullulan, or derivatives and the polysaccharide (chosen from alginic and / or hyaluronic acid, salts or derivatives) is in the range 1 / 0.002 - 1 / 200, advantageously in the range 1 / 0.2 - 1 / 20, even more advantageously in the range 1 / 1 - 1 / 3.

[0061] In a first embodiment, the combination according to the invention contains a mixture of pullulan, optionally in the form of a derivative, and hyaluronic acid, optionally in the form of a salt or derivative, in particular esterified, advantageously in the form of sodium hyaluronate. Advantageously, for a quantity x (in g) of pullulan, or derivatives, in particular esterified, the quantity of hyaluronic acid, salts or derivatives, in particular esterified, will be between 0.00 lx and 100x. In particular, the weight ratio of pullulan, or derivatives, in particular esterified / hyaluronic acid, salts or derivatives, in particular esterified, is in the range 1 / 0.001 - 1 / 100, advantageously in the range 1 / 0.1 - 1 / 10, even more advantageously it is 1 / 1.In a second embodiment, the combination according to the invention contains a mixture of pullulan, optionally in the form of a derivative, and alginic acid, optionally in the form of a salt or derivative, in particular esterified, advantageously in the form of propylene glycol alginate. Advantageously, for a quantity x (in g) of pullulan, or derivatives, in particular esterified, the quantity of alginic acid, salts or derivatives, in particular esterified, will be between 0.00 lx and 100x. In particular, the weight ratio of pullulan or derivatives, in particular esterified / alginic acid, salts or derivatives, in particular esterified, is in the range 1 / 0.001 - 1 / 100, advantageously in the range 1 / 0.1 - 1 / 10, even more advantageously in the range 1 / 1 - 1 / 2.

[0062] In a third embodiment, the combination according to the invention contains a mixture of pullulan, optionally in the form of a derivative, hyaluronic acid, optionally in the form of a salt or derivative, in particular esterified, advantageously in the form of sodium hyaluronate, and alginic acid, optionally in the form of a salt or derivative, in particular esterified, advantageously in the form of propylene glycol alginate. It therefore comprises these three compounds.

[0063] According to this third embodiment, advantageously, the combination according to the invention therefore comprises pullulan, sodium hyaluronate and propylene glycol alginate. Advantageously, the weight ratio of pullulan, optionally in the form of derivatives / hyaluronic acid, salts or esterified derivatives, / alginic acid, salts or esterified derivatives, is in the range 1 / 0.001 / 0.001 to 1 / 100 / 100, still advantageously in the range 1 / 0, 1 / 0.1 to 1 / 10 / 10, even more advantageously in the range 1 / 1 / 1 to 1 / 10 / 10, and still preferentially in the range 1 / 1 / 1 to 1 / 2 / 5.According to a preferred embodiment, this ratio is approximately 1 / 1 / 2, even more preferably it is According to this advantageous embodiment, said combination according to the invention forms a multi-layered molecular network, corresponding to a molecular mesh with the formation of hydrogen bonds, when the 3 pullulan compounds, optionally in the form of derivatives, hyaluronic acid, salts or esterified derivatives, and alginic acid, salts or esterified derivatives are combined concomitantly, preferably in the form of a premix, preferably at a ratio in the range 1 / 1 / 1 to 1 / 10 / 10, and even more preferably in the range 1 / 1 / 1 to 1 / 2 / 5, advantageously a ratio of 1 / 1 / 2.

[0064] Furthermore, this combination, in particular when it comprises the three compounds: pullulan, optionally in the form of derivatives, hyaluronic acid, salts or esterified derivatives, and alginic acid, salts or esterified derivatives, has in fact a reinforced activity, in a lasting manner, and this in particular due to the formation of a molecular network when the 3 pullulan compounds, optionally in the form of derivatives, hyaluronic acid, salts or esterified derivatives, and alginic acid, salts or esterified derivatives, are combined concomitantly, preferably in the form of a premix, preferably at a ratio in the range 1 / 1 / 1 to 1 / 10 / 10, and still preferably in the range 1 / 1 / 1 to 1 / 2 / 5, advantageously a ratio of 1 / 1 / 2.

[0065] Succinic acid or 1,4-butanedioic acid (CAS 110-15-6) can be used in its acid molecule forms or salts and / or derivatives, particularly esters compatible with cosmetic and / or pharmaceutical use.

[0066] Among the salts of succinic acid, we can cite monosodium or disodium succinate.

[0067] Among the succinic acid derivatives, we can cite the cholesterol ester: cholesterol succinate.

[0068] Succinic acid can in particular be extracted from sugar cane by biotechnological extraction process. Preferably, succinic acid, optionally in the form of one of its salts and / or derivatives, is present in the combination at a content of 0.1% to 10%, preferably between 1% and 5%, more preferably 2% by weight of dry matter relative to the total weight of the combination.

[0069] According to a particularly advantageous embodiment of the invention, succinic acid is present in the combination at a weight ratio of succinic acid, salts or derivatives / lactic acid, salts or derivatives being in the range 1 / 2 to 1 / 5, preferably 1 / 3 to 1 / 4.

[0070] Lactic acid or 2-hydroxypropanoic acid can be used in its acid molecule forms or salts and / or derivatives, particularly esters, compatible with cosmetic and / or pharmaceutical use.

[0071] Examples of lactic acid salts include sodium lactate, potassium lactate, magnesium lactate, and zinc lactate.

[0072] Among the lactic acid derivatives, we can cite esterified derivatives, in particular isostearyl, stearyl and ethyl lactate.

[0073] Lactic acid can be extracted from beetroot using a biotechnological extraction process.

[0074] Preferably, lactic acid, optionally in the form of one of its salts and / or derivatives, is present in the combination at a content of 1% to 15%, preferably between 3% and 9%, still preferably 6.75% by weight of dry matter relative to the total weight of the combination.

[0075] According to a particularly advantageous embodiment of the invention, lactic acid is present in the combination at a weight ratio of lactic acid, salts or derivatives / sucrose, salts or derivatives being in the range 1 / 1 to 1 / 3, preferably 1 / 1 to 1 / 2.

[0076] Sucrose, otherwise known as saccharose, can be used as such or in the form of a salt or derivative suitable for cosmetic and / or pharmaceutical use. Examples of salts include sucrose octosulfate salts, including potassium sucrose octosulfate.

[0077] Among the derivatives, we can cite as an example sucrose esters (or sucroester) in particular of fatty acids such as sucrose palmitate, sucrose cocoate, sucrose laurate, sucrose polystearate, sucrose polyoleate.

[0078] Sucrose can be extracted from beetroot using a biotechnological extraction process.

[0079] Preferably, sucrose, optionally in the form of one of its salts and / or derivatives, is present in the combination at a content of 1% to 15%, preferably between 3% and 9%, still preferably 7.5% by weight of dry matter relative to the total weight of the combination.

[0080] According to a particularly advantageous embodiment of the invention, succinic acid, lactic acid and sucrose are present in the combination at a weight ratio of succinic acid, salts or derivatives / lactic acid, salts or derivatives / sucrose, salts or derivatives in the range 1 / 2 / 2 to 1 / 4 / 15, preferably 1 / 3 / 3 to 1 / 4 / 8.

[0081] For the purposes of the present invention, the term "combination" means that the compounds (pullulan, alginic acid and / or hyaluronic acid, lactic acid, succinic acid and sucrose, optionally in the form of their respective salts and / or derivatives) are used together, preferably in the form of a premix. Advantageously, there is no covalent bond between the different compounds of the combination.

[0082] For the purposes of the present invention, the term "cosmetic use" means a non-therapeutic use, i.e. one which is not intended for therapeutic use and is intended for and / or applied to a so-called healthy part of the body, in particular to an area of ​​the skin and / or mucous membranes, so-called healthy. For the purposes of the present invention, the term "skin" means any part of the body and / or face, including the scalp.

[0083] For the purposes of the present invention, the term "mucosa(s)" means the mucosa on which acnes are present, in particular the ocular mucosa, the nasal mucosa, the oral mucosa, in particular the labial buccal mucosa and / or the gingival mucosa, preferably the ocular and / or oral mucosa, and even more preferably the labial and / or ocular mucosa.

[0084] For the purposes of the present invention, the term "healthy skin and / or healthy mucous membranes" or "healthy tissue" means an area of ​​skin, skin appendage or mucous membrane, to which the combination or mixture of ingredients or the composition according to the invention is applied and which is said to be "non-pathological" by a dermatologist, i.e. not exhibiting infection, in particular bacterial, scar, disease or skin condition such as candidiasis or dermatophytosis, impetigo, psoriasis, eczema, acne, ulcers, herpes or dermatitis, rosacea, telangiectasia, solar elastosis and / or cutis laxa pathology or wounds or injuries, boils, pustules, papules, folliculitis, abscesses, sycosis, inflammation, erythema, in particular nappy rash, ecthyma, erysipelas, marks scars, in particular pigment spots and / or acne scars. Advantageously, the combination according to the invention is not intended for atopic skin.

[0085] For the purposes of the present invention, the term "reduce and / or limit the virulence of a bacterium" means at least partially inhibiting or limiting the adhesion to the skin and / or mucous membranes of this bacterium and / or at least partially inhibiting or limiting the production of virulence factors such as the production of biofilm by this bacterium.

[0086] Adhesion to skin and / or mucous membranes of C. acnes can be measured as described in Example 3. Biofilm production by C. acnes can be measured as described in Example 2.

[0087] The effect of a product on the virulence of C. acnes is thus evaluated by measuring the adhesion of C. acnes to the skin and / or mucous membranes and / or by measuring the production of biofilm by C. acnes in the presence of the tested product and by comparing the results to those obtained in the absence of the tested product. Preferably, the reduction in the virulence of C. acnes, preferably of the adhesion of C. acnes to the skin and / or mucous membranes and / or of the production of biofilm by C. acnes is at least 10%, preferably at least 20%, still preferably 30% compared to the results obtained without treatment.

[0088] Here, the term "preventing and / or reducing unsightly and / or unpleasant and / or uncomfortable manifestations due to the virulence of C. acnes" means preventing the appearance of unsightly and / or unpleasant and / or uncomfortable manifestations and / or reducing their extent in healthy skin, healthy hair and / or healthy body hair and / or healthy mucous membranes, and not preventing or treating a pathology. This is therefore a cosmetic use and not a therapeutic treatment.

[0089] Thus, advantageously, the cosmetic use according to the invention (and therefore non-therapeutic) is to prevent and / or reduce and / or eliminate the unsightly and / or unpleasant and / or uncomfortable manifestations due to the virulence of C. acnes, in particular to prevent and / or reduce and / or delay the secretion of sebum and its unsightly and / or unpleasant and / or uncomfortable manifestations, in particular to prevent and / or reduce and / or delay the formation of blackheads and / or comedogenesis, and / or prevent and / or reduce the visibility of skin pores, and / or maintain and / or improve the homogeneity and / or radiance and / or luminosity of the complexion of the skin and / or mucous membranes, for example by eliminating and / or reducing redness and / or irregularities, and / or prevent and / or treat the sensation of heating of the skin and / or mucous membranes, and / or to prevent and / or reduce hair loss and / or body hair, and / or to prevent and / or reduce dandruff.

[0090] For the purposes of the present invention, the expression "reducing the visibility of skin pores" means tightening skin pores, i.e. reducing the opening diameter of the pores, and / or the density and / or the area of ​​the pores on the surface of the skin, and / or preventing the dilation of skin pores. The combination according to the invention makes it possible to reduce the opening and / or the density of the pores on the surface of the skin.

[0091] The visibility of skin pores can be demonstrated in vivo by a so-called "scoring" evaluation by a dermatologist on a predefined area after application of a composition comprising the combination according to the invention. It can also be demonstrated by an objective instrumental method by image analysis making it possible to extract and quantify specific parameters from high-resolution photographs in cross-polarized configuration of the face of volunteers before and after application of a composition comprising the combination according to the invention.

[0092] The density of skin pores can also be measured in vivo by imaging, particularly using the fringe projection technique, by measuring the so-called curvature parameter.

[0093] In a preferred embodiment of the invention, the combination according to the invention is in an effective amount to reduce the visibility of the pores of the skin by at least 10%, preferably by at least 20%, after 28 days of application of a cream comprising the combination according to the invention, preferably formulated in the form of a cosmetic composition such as that described in the examples.

[0094] For the purposes of the present invention, the term "maintaining and / or improving the homogeneity and / or radiance and / or luminosity of the complexion of the skin and / or mucous membranes" means preventing and / or reducing and / or treating imperfections in the complexion, such as redness or irregularities of the skin, making the complexion of the skin and / or mucous membranes more homogeneous and therefore less dull and more luminous, and / or reducing the reddish appearance of the skin by giving it a healthy and / or nourished appearance and therefore a healthy glow.

[0095] The measurement of the homogeneity, radiance and / or luminosity of skin tone can, for example, be measured by chromametry or by image analysis. The latter in vivo measurement method consists of taking high-resolution photographs in a crossed polarized configuration of the face of volunteers taken at 45° before and after application of the tested product. Based on these digital photographs, an image analysis makes it possible to extract and quantify specific parameters (for example: L*, a*, b*, C, h°) related to the color, radiance, homogeneity, and texture of the skin.

[0096] Advantageously, the term "reduce hair and / or body hair loss" means reducing by at least 0.5%, preferably by at least 1%, more preferably by at least 2% the density of hair or body hair in the telogen phase, i.e. in the shedding phase. The measurement of the density of hair and / or body hair in the telogen phase and in the anagen phase may be measured by in vivo measurement, by the phototrichogram technique, in the presence of the combination according to the invention or of a composition comprising it, in particular a formulation in the form of a shampoo, in comparison with the density of hair or body hair in the telogen and anagen phase measured without the combination according to the invention or without a composition comprising it.

[0097] In an advantageous embodiment, the combination is applied topically, advantageously to specific parts of the body chosen: the body, the face, in particular the forehead, the cheeks, the nose, the so-called "T" zone (forehead, nose and chin), the neck and the contour of the lips, the scalp, the shoulders, the arms, the back, the torso, the décolleté, the ocular mucosa, the nasal mucosa, the oral mucosa, in particular the labial buccal mucosa and / or the gingival mucosa, the excessively cleaned areas and / or the area of ​​skin or mucosa whose skin barrier has been altered, for example due to a mechanical, chemical or biological action, such as sunburn (solar erythema), the action of a razor, the use of unsuitable or overly astringent cleaning products, pollution, the use of antibiotics, allergens, etc.

[0098] For the purposes of the present invention, the term "topical route" means the application of the combination and / or composition and / or mixture of ingredients according to the invention to the surface of the skin and / or mucous membranes, in particular by direct application or by vaporization.

[0099] For the purposes of the present invention, the term "cosmetic and / or pharmaceutical ingredient(s)" means one or more plant extracts and / or one or more natural or synthetic molecules and / or their mixtures intended for a cosmetic and / or pharmaceutical application. Cosmetic ingredients are defined in particular by the international nomenclature of cosmetic ingredients (INCI).

[0100] The term "cosmetic or pharmaceutical active ingredient" means a cosmetic or pharmaceutical ingredient with cosmetic and / or pharmaceutical efficacy. Pharmaceutical active ingredients correspond to active pharmaceutical principles. Categories and examples of cosmetic and / or pharmaceutical active ingredients are provided below.

[0101] For the purposes of the present invention, the term "suitable cosmetic or pharmaceutical vehicle" means that the composition or components thereof are suitable for use in contact with human skin and / or mucous membranes without undue toxicity, incompatibility, instability, allergic response, or their equivalents. Advantageously, the combination according to the invention comprises, in particular is constituted by:

[0102] - pullulan or one of its derivatives, advantageously pullulan,

[0103] - hyaluronic acid, one of its salts or derivatives, advantageously sodium hyaluronate,

[0104] - alginic acid, one of its salts or derivatives, advantageously propylene glycol alginate,

[0105] - lactic acid, one of its salts or derivatives, advantageously lactic acid,

[0106] - succinic acid, one of its salts or derivatives, advantageously succinic acid and

[0107] - sucrose, one of its salts or derivatives, advantageously sucrose. It therefore comprises, in particular it is made up of, 6 ingredients.

[0108] The combination according to the invention, and preferably in the form of the 6 compounds (pullulan or its derivative, hyaluronic acid or its salt or derivative, alginic acid or its salt or derivative, lactic acid or its salt or derivative, succinic acid or its salt or derivative and sucrose or its derivative) is preferably used alone or in the form of a mixture of cosmetic or pharmaceutical ingredients further comprising a cosmetic or pharmaceutical vehicle, in particular a dermatological vehicle, suitable for its formulation and / or its integration into a cosmetic or pharmaceutical composition, in particular a dermatological composition. The combination according to the invention can also be used in a cosmetic or pharmaceutical composition, in particular a dermatological composition, i.e. with an appropriate cosmetic or pharmaceutical vehicle, in particular a suitable dermatological vehicle, and preferably intended for topical administration.Preferably, said combination according to the invention comprises, in particular consists of a mixture of the 6 compounds (pullulan or its derivative, hyaluronic acid or its salt or derivative, alginic acid or its salt or derivative, lactic acid or its salt or derivative, succinic acid or its salt or derivative and sucrose or its salt or derivative) preferably at a ratio in the range 1 / 1 / 1 / 1 / 1 / 1 to 1 / 10 / 10 / 300 / 100 / 300, and more preferably in the range 1 / 1 / 1 / 10 / 5 / 10 to 1 / 2 / 5 / 100 / 50 / 100, more preferably in the range 1 / 1 / 1 / 20 / 5 / 20 to 1 / 1 / 2 / 30 / 10 / 35, advantageously a ratio of 1 / 1 / 2 / 24 / 8 / 30.

[0109] According to a particular embodiment, the combination according to the invention, preferably the combination of the 6 compounds, is in the form of a mixture of cosmetic or pharmaceutical ingredients, in particular dermatological ingredients, advantageously intended to be incorporated into a cosmetic or pharmaceutical composition, in particular dermatological, further comprising a suitable cosmetic or pharmaceutical vehicle. Advantageously, the vehicle of the mixture of cosmetic or pharmaceutical ingredients is and / or contains water. The present invention further relates to a mixture of cosmetic or pharmaceutical ingredients intended to be incorporated into a cosmetic or pharmaceutical composition, said mixture comprising the combination according to the invention and a suitable cosmetic or pharmaceutical vehicle.

[0110] Advantageously, the combination according to the invention is included in the mixture of cosmetic or pharmaceutical ingredients, in particular dermatological ingredients, at a content of 0.001% to 30% by weight of dry matter relative to the total weight of the mixture of cosmetic or pharmaceutical ingredients, more advantageously between 0.01 and 20% by weight, even more advantageously between 0.1 and 20% by weight, in particular between 0.25 and 20% by weight, more particularly between 1 and 20% by weight of dry matter relative to the total weight of the mixture of cosmetic or pharmaceutical ingredients, preferably in association with glycerin and / or xanthan gum and / or pentylene glycol, and / or caprylyl glycol and / or water, still advantageously xanthan gum and / or glycerin.

[0111] According to an advantageous embodiment, the mixture of cosmetic or pharmaceutical ingredients, in particular dermatological ingredients, comprises on the one hand: pullulan or one of its cosmetically or pharmaceutically acceptable derivatives in a content of between 0.0001 and 10% by weight of dry matter relative to the total weight of the mixture of ingredients, more advantageously between 0.001% and 5% by weight, even more advantageously between 0.01 and 3% by weight, in particular between 0.1 and 1% by weight, even more particularly between 0.25 and 0.5% by weight, very particularly 0.25% by weight relative to the total weight of the mixture of ingredients and

[0112] - hyaluronic acid or one of its cosmetically or pharmaceutically acceptable salts or derivatives in a content of between 0.0001 and 10% by weight of dry matter relative to the total weight of the mixture of ingredients, advantageously between 0.001% and 5% by weight, more advantageously between 0.01 and 3% by weight, in particular between 0.1 and 1% by weight, more particularly between 0.1 and 1% by weight, even more particularly between 0.25 and 0.5% by weight, very particularly 0.25% by weight relative to the total weight of the mixture of ingredients and / or

[0113] - alginic acid or one of its cosmetically or pharmaceutically acceptable salts or derivatives in a content of between 0.0001 and 10% by weight of dry matter relative to the total weight of the mixture of ingredients, advantageously between 0.001% and 5% by weight, more advantageously between 0.01 and 3% by weight, even more advantageously between 0.1 and 2% by weight, even more particularly 0.5% by weight relative to the total weight of the mixture of ingredients, and on the other hand:

[0114] - succinic acid or one of its cosmetically or pharmaceutically acceptable salts or derivatives in a content of between 0.1 and 10% by weight of dry matter relative to the total weight of the mixture of ingredients, advantageously between 0.1 and 10% by weight, more advantageously between 1 and 5% by weight, even more particularly 2% by weight relative to the total weight of the mixture of ingredients and

[0115] - lactic acid or one of its cosmetically or pharmaceutically acceptable salts or derivatives in a content of between 1 and 15% by weight of dry matter relative to the total weight of the mixture of ingredients, advantageously between 3 and 9% by weight, even more particularly 6% by weight relative to the total weight of the mixture of ingredients and

[0116] - sucrose or one of its cosmetically or pharmaceutically acceptable salts or derivatives in a content of between 1 and 15% by weight of dry matter relative to the total weight of the mixture of ingredients, advantageously between 3 and 9% by weight, even more particularly 7.5% by weight relative to the total weight of the mixture of ingredients.

[0117] According to a preferred embodiment, the mixture of cosmetic or pharmaceutical ingredients comprises the combination of pullulan or one of its derivatives, hyaluronic acid or one of its salts or derivatives and alginic acid or one of its salts or derivatives, preferably at a ratio of between 1 / 1 / 1 and 1 / 10 / 10, preferably between 1 / 1 / 1 and 1 / 2 / 5, still preferably at a ratio of 1 / 1 / 2.

[0118] In an advantageous embodiment, the mixture of cosmetic or pharmaceutical ingredients according to the invention further comprises xanthan gum and / or glycerin and / or water.

[0119] In particular, the mixture of cosmetic or pharmaceutical ingredients according to the invention is in liquid form.

[0120] Advantageously, the mixture of cosmetic or pharmaceutical ingredients according to the invention then contains a polar solvent, such as water, an alcohol, a polyol, a glycol, such as pentylene glycol and / or butylene glycol and / or hexylene glycol and / or caprylyl glycol, or one of their mixtures, preferably a hydroglycolic mixture, still preferably containing a glycol chosen from hexylene glycol, pentylene glycol, caprylyl glycol and their mixtures, or glycerol.

[0121] Advantageously, the mixture of cosmetic or pharmaceutical ingredients contains pentylene glycol, in particular between 0.1 and 10%, preferably between 0.5 and 5%, even more preferably between 1 and 3% by weight of pentylene glycol, relative to the total weight of the mixture of cosmetic ingredients.

[0122] Advantageously, the mixture of ingredients contains caprylyl glycol, in particular containing between 0.01 and 10%, preferably between 0.1 and 5%, more preferably between 0.3 and 1% by weight of caprylyl glycol, relative to the total weight of the mixture of cosmetic ingredients.

[0123] The combination, in particular in the form of a mixture of cosmetic or pharmaceutical ingredients, in particular dermatological ingredients, according to the invention can be used in a cosmetic or pharmaceutical composition, in particular dermatological composition, preferably at a content by weight of dry matter relative to the total weight of the composition of between 0.1 and 10%, advantageously between 0.1 and 5%, in particular between 0.1 and 3%.

[0124] The present invention further relates to a cosmetic or pharmaceutical composition intended for topical administration comprising the combination according to the invention or the mixture of cosmetic or pharmaceutical ingredients according to the invention and a suitable cosmetic or pharmaceutical vehicle.

[0125] In an advantageous embodiment, in particular if the mixture of cosmetic or pharmaceutical ingredients does not already contain any, the cosmetic or pharmaceutical composition according to the invention further comprises xanthan gum and / or glycerin and / or pentylene glycol and / or caprylyl glycol. In another embodiment of the present invention, the combination according to the invention or the mixture of cosmetic or pharmaceutical ingredients comprising it according to the invention is in the form of a cosmetic or pharmaceutical composition, in particular dermatological, intended for topical administration further comprising a suitable cosmetic or pharmaceutical vehicle.

[0126] Thus, in this embodiment of the present invention, the combination according to the invention is included in a cosmetic or pharmaceutical composition, in particular a dermatological composition, in particular intended to be administered to a human being, preferably by topical application, preferably cutaneous. Advantageously, the combination according to the present invention is then included in the composition at a content of between 0.0001% and 20% by weight of total dry matter relative to the total weight of the composition, between 0.0005% and 10%, more advantageously between 0.005 and 10% by weight, even more advantageously between 0.005 and 5% by weight, in particular between 0.005 and 1% by weight, of total dry matter relative to the total weight of the composition. The cosmetic or pharmaceutical composition according to the invention, in particular a dermatological composition, preferably also contains a cosmetic and / or pharmaceutical, in particular dermatological, vehicle and / or excipient.

[0127] According to an advantageous embodiment, the cosmetic or pharmaceutical composition, in particular dermatological, according to the invention comprises on the one hand: pullulan or one of its cosmetically or pharmaceutically acceptable derivatives in an amount of between 0.0001 and 10% by weight of dry matter relative to the total weight of the composition, and advantageously an amount of between 0.001% and 5% by weight, more advantageously between 0.001 and 3% by weight, in particular between 0.002 and 0.1% by weight, more preferably between 0.002 and 0.075% by weight, and

[0128] - hyaluronic acid or one of its cosmetically or pharmaceutically acceptable salts or derivatives in a content of between 0.0001 and 10% by weight of dry matter relative to the total weight of dry matter of the composition, advantageously between 0.001% and 5% by weight, more advantageously between 0.001 and 3% by weight, in particular between 0.002 and 0.1% by weight, more preferably between 0.002 and 0.075% by weight and / or

[0129] - alginic acid or one of its cosmetically or pharmaceutically acceptable salts or derivatives in a content of between 0.0001 and 10% by weight of dry matter relative to the total weight of the composition, advantageously between 0.001% and 5% by weight, more advantageously between 0.001 and 1% by weight, in particular between 0.005 and 0.1% by weight, even more particularly between 0.005 and 0.015% by weight, and on the other hand:

[0130] - succinic acid or one of its cosmetically or pharmaceutically acceptable salts or derivatives in a content of between 0.001 and 5% by weight of dry matter relative to the total weight of the mixture of ingredients, advantageously between 0.001 and 1% by weight, more advantageously between 0.001 and 0.1% by weight, even more advantageously between 0.01% and 0.05% by weight, even more particularly 0.04% by weight and

[0131] - lactic acid or one of its cosmetically or pharmaceutically acceptable salts or derivatives in a content of between 0.001 and 10% by weight of dry matter relative to the total weight of the mixture of ingredients, advantageously between 0.001 and 5% by weight, more advantageously between 0.01 and 1% by weight, even more advantageously between 0.1 and 0.5% by weight, even more particularly 0.12% by weight and

[0132] - sucrose or cosmetically or pharmaceutically acceptable derivatives in a content of between 0.001 and 10% by weight of dry matter relative to the total weight of the mixture of ingredients, advantageously between 0.001 and 5% by weight, more advantageously between 0.01 and 1% by weight, even more advantageously between 0.1 and 0.5% by weight, even more particularly 0.15% by weight.

[0133] According to a preferred embodiment, the cosmetic or pharmaceutical composition contains the combination of pullulan or one of its derivatives, hyaluronic acid, or one of its salts or derivatives and alginic acid or one of its salts or derivatives, preferably at a ratio of 1 / 1 / 2.

[0134] The cosmetic or pharmaceutical composition or the mixture of cosmetic or pharmaceutical ingredients according to the invention may be presented in all the galenic forms conventionally used for topical application, such as liquid or solid forms or even in the form of liquid under pressure.They may in particular be formulated in the form of an aqueous or oily solution, a cream or an aqueous gel or an oily gel, in particular in a pot or tube, in particular a shower gel, a shampoo, a milk, an emulsion, a hydrogel, a microemulsion or a nanoemulsion, in particular oil-in-water or water-in-oil or multiple or silicone, a serum, a lotion, in particular in a glass or plastic bottle or in a dosing bottle or in an aerosol, an ampoule, a liquid soap, a paste, a dermatological bar, an ointment, a mousse, a mask, a patch, an anhydrous product, preferably liquid, pasty or solid, for example in the form of a stick, in particular a stick, or in powders, in particular makeup.In particular, the composition is in the form of a serum, a lotion, a cream, a milk, an ointment, a paste, a mousse, an emulsion, a hydrogel, a shower gel, a mask, a stick, a patch, or makeup powders, advantageously a cream or a lotion.

[0135] The compositions according to the invention may contain any suitable solvent and / or any suitable vehicle and / or any suitable excipient, optionally in combination with other compounds of interest. They may in particular contain a cosmetically or dermatologically acceptable excipient chosen from surfactants, preservatives, buffering agents, bulking agents, chelating agents, biocidal agents, denaturants, opacifying agents, pH adjusters, reducing agents, stabilizing agents, emulsifiers, thickeners, gelling agents, film-forming polymers, solvents, fillers, bactericides, odor absorbers, matting agents, conditioning agents, texturizing agents, shine agents, pigments, dyes, perfumes and chemical or mineral sunscreens, trace elements, essential oils. These combinations are also covered by the present invention.The CTFA Cosmetic Ingredient Handbook, Second Edition (1992) describes various cosmetic and pharmaceutical ingredients commonly used in the cosmetic and pharmaceutical industry, which are particularly suitable for topical use.

[0136] Preferably, the compositions according to the invention in the form of a mixture of cosmetic or pharmaceutical ingredients or of a cosmetic or pharmaceutical composition contain at least one other cosmetic or pharmaceutical active ingredient, in particular dermatological, and preferably from one to three cosmetic or pharmaceutical active ingredients, in particular dermatological, preferably having complementary properties on the virulence factors and / or on the unsightly and / or unpleasant and / or uncomfortable manifestations due to the virulence of C. acnes, in particular the secretion of sebum, the formation of blackheads and / or comedogenesis, the visibility of skin pores, the homogeneity and / or the radiance and / or the luminosity of the complexion of the skin and / or the mucous membranes, the sensation of heating of the skin and / or the mucous membranes, the loss of hair and / or body hair and / or the appearance of dandruff.

[0137] This may include one or more other ingredients active on the cutaneous and / or mucosal microbial flora and / or active on the skin barrier function, in particular moisturizing and / or soothing active ingredients, including an oligosaccharide obtained by enzymatic synthesis marketed by the company Solabia under the name BioEcolia™ or an alpha-glucooligosaccharide complex marketed by the same company under the name Ecoskin™, an 'Aiisma p / antago-aquatica' extract, an Argania spinosa extract (Lipofructyl™ Argan, a mixture of ceramides (Sphingoceryl™ VEG), purifying extracts of Boldo (Betapur™), products based on inulin or fructooligosaccharides, bifidobacteria extracts or an Orthosiphon stamineus extract to combat oily skin (MAT-XS™ Bright), a natural extract honey marketed by the applicant under the name Melhydran™ for its moisturizing properties,a flax extract marketed under the name Oligolin™ by the applicant, a biotechnologically modified yeast extract marketed by the applicant under the name Relipidium™, a Pueraria lobata root extract marketed under the name Inhipase™ by the applicant, a beta-glucan derivative from baker's yeast marketed by Mibelle under the name CM-Glucan Forte™ and / or a Mirabilis jaiapa extract marketed under the name Pacifeel™ by Sederma.,

[0138] These may be cosmetic ingredients having a complementary effect such as those chosen from salicylic acid, niacinamide, zinc gluconate, an extract of Bixa oreiiana seeds (for example Bix-Activ™) and / or N-methyl glycine (for example Scalposine™). The present invention further relates to the cosmetic use of the combination according to the invention or of the mixture of cosmetic ingredients according to the invention or of the cosmetic composition according to the invention for limiting and / or reducing the virulence of Cutibacterium acnes on the skin and / or mucous membranes, in particular by at least one of the following mechanisms:

[0139] - by inhibiting or limiting the adhesion of Cutibacterium denes,'

[0140] - by inhibiting or limiting the production of virulence factors of Cutibacterium acnes such as biofilm.

[0141] The present invention thus relates to the cosmetic use of the combination according to the invention, alone or in the form of a mixture of cosmetic ingredients or a cosmetic composition according to the present invention, to limit and / or reduce the virulence of Cutibacterium acnes, in particular the formation of biofilm, in order to prevent and / or reduce the uncomfortable and / or unpleasant and / or unsightly manifestations of the virulence factors of Cutibacterium acnes.

[0142] Advantageously, the cosmetic use according to the invention (and therefore non-therapeutic) is to prevent and / or reduce and / or eliminate the unsightly and / or unpleasant and / or uncomfortable manifestations due to the virulence of C. acnes, in particular to prevent and / or reduce and / or delay the secretion of sebum and its unsightly and / or unpleasant and / or uncomfortable manifestations, in particular to prevent and / or reduce and / or delay the formation of blackheads and / or comedogenesis, prevent and / or reduce the visibility of skin pores and / or maintain and / or improve the homogeneity and / or radiance and / or luminosity of the complexion of the skin and / or mucous membranes, and / or prevent and / or treat the sensation of heating of the skin and / or mucous membranes, and / or to prevent and / or reduce hair loss and / or body hair and / or to prevent and / or reduce dandruff.The combination, the mixture of cosmetic or pharmaceutical ingredients, in particular dermatological ingredients, according to the invention is topically acceptable.

[0143] For the purposes of the present invention, the term "topically acceptable" means an ingredient suitable for topical application, non-toxic, non-irritating to the skin and / or mucous membranes and / or the scalp, not inducing an allergic response, which is not chemically unstable.

[0144] The combination according to the invention, in particular in the form of a cosmetic or pharmaceutical composition, in particular a dermatological one, is therefore particularly suitable for the care and / or treatment of skin and / or mucous membranes with a large quantity of cutaneous and / or mucosal C. acnes such as the face, in particular the forehead, the cheeks and / or the contour of the lips, the shoulders, the arms, the back, the torso, the décolleté, the ocular, nasal, oral mucosa, in particular the labial oral mucosa and / or the gingival mucosa, excessively cleaned areas, and / or the area of ​​skin or mucosa whose skin barrier has been altered, for example due to a mechanical, chemical or biological action, such as sunburn (solar erythema), the action of a razor, the use of unsuitable or overly astringent cleaning products, pollution, the use of antibiotics, allergens, etc.The combination according to the invention is also particularly suitable for use on the mucous membranes, alone or in the form of a cosmetic or dermatological composition, in particular for limiting and / or reducing the mucosal virulence of Cutibacterium acnes, advantageously for preventing and / or reducing and / or eliminating the unsightly and / or unpleasant and / or uncomfortable manifestations due to the virulence of Cutibacterium acnes, in particular for maintaining and / or increasing and / or improving the homogeneity and / or radiance and / or luminosity of the complexion of the mucous membranes and / or preventing and / or treating the sensation of heating of the mucous membranes.

[0145] The combination according to the invention, alone or in the form of a cosmetic or pharmaceutical composition or a mixture of cosmetic or pharmaceutical ingredients, can be applied to all or part of the human body, preferably chosen from the body, the face, in particular the forehead, the cheeks, the chin, the nose, the so-called "T" zone (forehead, nose and chin), the neck and the contour of the lips, the scalp, the shoulders, the arms, the back, the torso, the décolleté, the ocular mucosa, the nasal mucosa, the oral mucosa, in particular the labial buccal mucosa and / or the gingival mucosa, excessively cleansed areas and / or the area of ​​skin or mucosa whose skin barrier has been altered, for example due to a mechanical, chemical or biological action, such as sunburn (solar erythema), the action of a razor, the use of unsuitable or overly astringent cleaning products, pollution, the use of antibiotics,by allergens etc.,

[0146] The present invention further relates to the combination according to the invention, advantageously in the form of a mixture of pharmaceutical ingredients or in the form of a pharmaceutical composition, in particular a dermatological composition, according to the present invention for its use as a pharmaceutical active ingredient, in particular a dermatological active ingredient, in particular in the treatment and / or prevention and / or reduction of the occurrence of pathologies due to the virulence of C. acnes, advantageously involving an increase in the secretion of biofilm and / or an increase in the adhesion of C.acne, advantageously pathologies chosen from the group consisting of bacterial infections of the skin and / or mucous membranes, pustules, papules, boils, folliculitis, abscesses, acne, in particular superinfected, wounds in particular superinfected, inflammation of the skin and / or mucous membranes, and / or in the prevention of scar marks, in particular pigment spots and / or acne scars.

[0147] Finally, the present invention relates to a cosmetic (and therefore non-therapeutic) care method, characterized in that it comprises the application to at least one relevant area of ​​the skin and / or mucous membranes of the face and / or body, of the combination according to the present invention or of a cosmetic composition or of a mixture of cosmetic ingredients comprising, as active agent, the combination according to the invention as defined above, to prevent and / or reduce and / or eliminate the unsightly and / or unpleasant and / or uncomfortable manifestations due to the virulence of Cutibacterium acnes, in particular the formation of biofilm, in particular to prevent and / or reduce and / or delay the secretion of sebum and its unsightly and / or unpleasant and / or uncomfortable manifestations, more particularly to prevent and / or reduce and / or delay the formation of blackheads and / or comedogenesis,and / or prevent and / or reduce the visibility of skin pores and / or maintain and / or improve the homogeneity and / or radiance and / or luminosity of the complexion of the skin and / or mucous membranes, and / or prevent and / or treat the sensation of heating of the skin and / or mucous membranes, and / or to prevent and / or reduce hair loss and / or body hair, and / or to prevent and / or reduce dandruff.,

[0148] The present invention further relates to a cosmetic (and therefore non-therapeutic) care method for preventing and / or reducing and / or eliminating the unsightly and / or unpleasant and / or uncomfortable manifestations due to the virulence of Cutibacterium acnes, in particular the formation of biofilm, in particular for preventing and / or reducing and / or delaying the secretion of sebum and its unsightly and / or unpleasant and / or uncomfortable manifestations, more particularly for preventing and / or reducing and / or delaying the formation of blackheads and / or comedogenesis, and / or preventing and / or reducing the visibility of skin pores and / or maintaining and / or improving the homogeneity and / or radiance and / or luminosity of the complexion of the skin and / or mucous membranes, and / or preventing and / or treating the sensation of heating of the skin and / or mucous membranes, and / or for preventing and / or reducing hair loss and / or body hair, and / or for preventing and / or reducing dandruff,characterized in that it comprises the application to at least one relevant area of ​​the skin and / or mucous membranes of the face and / or body, of the combination according to the present invention or of a cosmetic composition or a mixture of cosmetic ingredients comprising, as active agent, the combination according to the invention as defined above. In particular, the method comprises the selection of an area of ​​the skin and / or mucous membranes for which it is necessary to prevent and / or reduce and / or eliminate the unsightly and / or unpleasant and / or uncomfortable manifestations due to the virulence of Cutibacterium acnes, more particularly the formation of biofilm, in particular to delay the secretion of sebum and its unsightly and / or unpleasant and / or uncomfortable manifestations, more particularly to reduce and / or delay the formation of blackheads and / or comedogenesis,and / or to prevent and / or reduce the visibility of skin pores and / or to maintain and / or improve the homogeneity and / or radiance and / or luminosity of the complexion of the skin and / or mucous membranes, and / or to prevent and / or treat the sensation of heating of the skin and / or mucous membranes, and / or to prevent and / or reduce hair loss and / or body hair, and / or to prevent and / or reduce dandruff, before the application of the combination according to the present invention or of a cosmetic composition or a mixture of cosmetic ingredients comprising, as active agent, the combination according to the invention as defined above, in particular in an effective amount.,

[0149] Advantageously, the area concerned of the skin and / or mucous membranes of the face or body is chosen from all or part of the human body, preferably chosen from the body, the face, in particular the forehead, the cheeks, the chin, the nose, the so-called "T" zone (forehead, nose and chin), the neck and the contour of the lips, the scalp, the shoulders, the arms, the back, the torso, the décolleté, the ocular mucosa, the nasal mucosa, the oral mucosa, in particular the labial buccal mucosa and / or the gingival mucosa, the excessively cleaned areas and / or the area of ​​skin or mucosa whose skin barrier has been altered for example due to a mechanical, chemical or biological action, such as sunburn (solar erythema), the action of a razor, the use of unsuitable or overly astringent cleaning products, pollution, the use of antibiotics, allergens, etc.

[0150] It further relates to a method of treatment and / or prevention and / or reduction of the occurrence of pathologies due to the virulence of C acnes, advantageously involving an increase in the secretion of biofilm and / or an increase in the adhesion of C.acne, advantageously of pathologies chosen from the group consisting of bacterial infections of the skin and / or mucous membranes, pustules, papules, boils, folliculitis, abscesses, acne, in particular superinfected, wounds in particular superinfected, inflammation of the skin and / or mucous membranes, and / or in the prevention of scar marks in particular pigment spots and / or acne scars, advantageously by application to at least one affected area of ​​the skin and / or mucous membranes of the face or body of a patient in need thereof, of an effective amount of the combination according to the present invention or of a pharmaceutical composition or of a mixture of pharmaceutical ingredients comprising as active agent, the combination according to the invention as defined above.

[0151] Other aims, characteristics and advantages of the invention will become clear to those skilled in the art upon reading the explanatory description which refers to examples which are given solely by way of illustration and which in no way limit the scope of the invention.

[0152] The examples are an integral part of the present invention and any feature appearing new over any prior art from the description taken as a whole, including the examples, is an integral part of the invention in its function and generality.

[0153] So each example has a general scope.

[0154] On the other hand, in the examples, and unless otherwise indicated, the temperature is expressed in degrees Celsius and the pressure is atmospheric pressure.

[0155] Examples

[0156] Example 1: Combination according to the invention

[0157] The combination according to the invention was obtained by simple mixing of the following compounds as indicated in Table 1 below:

[0158] [Table 1]

[0159] Example 2: Evaluation of the inhibition of the product according to the invention on the formation of biofilm by C acnes.

[0160] Protocol:

[0161] Cutibacterium acnes was collected from human skin (face) and phylotyped type I using the MLST (MultiLocus Sequencing Typing) method (bacteria called IA2 from the company Biofilm Control). It was grown on an agar plate under anaerobic conditions.

[0162] The product according to example 1 was tested and compared to two comparison products called Cl and C2 with the following composition: Product Cl corresponds to the product according to example 1 without the 3 compounds: succinic acid, lactic acid and sucrose and whose composition is indicated in table 2 below:

[0163] [Table 2]

[0164] Product C2: corresponds to the 3 compounds removed from the product of example 1 (and absent from product Cl) and whose composition is indicated in the following table 3:

[0165] [Table 3]

[0166] Each tested product was added to the well of a 96-well plate at 1% by volume relative to the total volume of the culture medium and the tested product. Each product was tested in triplicate, then the plates were kept overnight at -20°C and then the BioFilm Ring Test (BRT®) was performed (Biofilm Control). This test is based on the ability of bacteria to secrete exopolysaccharides present in the biofilm, which will immobilize the magnetic particles. C. acnes IA2 shows biofilm formation from 48 hours of incubation. Thus, the BRT was performed at 56 hours.

[0167] When the microplates were at room temperature, the initial bacterial suspension was prepared in BHI (Brain Heart Infusion) type culture medium, inoculated at 10 6CFU / mL estimated by absorbance measurement (OD 600nm) and each well was filled with the magnetic beads (TON004) at 10 pL / mL. Negative controls were prepared by mixing BHI with TON004 (10 pL / mL). Controls were also present in parallel to evaluate the mobility of the microbeads in the presence of the ingredients alone.

[0168] The microplates were incubated under anaerobic conditions at 37°C. After 56 hours, a contrast liquid was added to each well and the microplate was magnetized for 1 minute on the Block Test. The microplate was then scanned and analyzed with BFC Elements 3.0 software. When the biofilm is formed, the beads cannot move in the well. This corresponds to a 100% biofilm formed. In the presence of ingredients inhibiting biofilm formation, the beads will be able to aggregate in the center of the well. The rate of beads aggregating in the center of the well corresponds to the percentage of inhibition of biofilm formation.

[0169] Results are presented as percentage of C. acnes biofilm formation. The positive control corresponds to 100% biofilm formed by C. acnes bacteria alone.

[0170] The results are presented in Table 4: n=3; Avg. denotes the mean; SEM denotes the deviation from the mean.

[0171] [Table 4] The viability of C. acnes was verified at 56 hours in the presence of the product according to Example 1 at 1% (v / v) and no impact on the viability of C. acnes was observed. The product according to Example 1 therefore does not inhibit the growth of C. acnes.

[0172] Conclusion: The product according to the invention at the doses tested very significantly inhibited (t test carried out versus the positive control with a significance threshold p<0.001) the formation of C. acnes biofilm in a synergistic manner compared to its compounds tested separately.

[0173] Example 3: Evaluation of the inhibition of adhesion on C acnes by the product according to the invention.

[0174] Protocol

[0175] The bacterium C. acnes deposited in culture under the number ATCC6919 (Phylotype IA1) was cultivated anaerobically for 72 hours at 37°C in non-selective culture medium (Schaedler) in the absence (called “Untreated control”) or in the presence of the Product according to example 1 at 1% by volume relative to the total volume (culture medium + Product according to example 1).

[0176] The cultures were then centrifuged and the pellets were resuspended in alkaline phosphate buffer (PBS 1X Mg Ca) in the absence (called "Untreated Control") or in the presence of the Product according to Example 1 at 1% by volume relative to the total volume (culture medium + Product according to Example 1). The optical density OD at 600nm was adjusted to 0.8 per well (in n=11)

[0177] The cultures were placed anaerobically for 6 hours at 37°C to allow bacterial adhesion. Then, syto9 labeling was performed to allow observation of adherent bacteria under a confocal microscope (excitation / emission: 485 / 498nm).

[0178] Biomass analysis was performed using ComStat2 software. It is a volume calculation in pm 3 / pm 2 (corresponds to the biomass (in pm 3 ) divided by the area in pm 2 ). Counting the volume of Biomass in pm 3 / pm 2 SEM T-test vs untreated control.

[0179] The results are presented in the following Table 5: n=11; Avg. denotes the mean. SEM denotes the deviation from the mean. The statistical test used is the t test performed versus the untreated control with a significance threshold of p<0.01. S denotes a significant deviation from the mean.

[0180] [Table 5]

[0181] Conclusion: The product according to the invention inhibits the adhesion of C. acnes without impacting the viability of C. acnes.

[0182] Example 4 Mixture of cosmetic or pharmaceutical ingredients according to the invention containing the combination according to the invention

[0183] A mixture of cosmetic or pharmaceutical ingredients having the formulation indicated in Table 6 below in percentage by weight is prepared.

[0184] [Table 6]

[0185] Pentylene glycol, caprylyl glycol, glycerin, lactic acid, succinic acid and sucrose are first dissolved in water. The polymers (hyaluronic acid, pullulan, propylene glycol alginate and xanthan gum) are then added to this aqueous solution and the resulting mixture is kept stirring until a homogeneous product is obtained.

[0186] Example 5: Composition according to the invention in the form of a Lotion for the body and / or face

[0187] [Table 7] The lotion is prepared by the usual methods in the field well known to those skilled in the art, by mixing the 6 phases.

Claims

Demands 1. Combination including: - pullulan or one of its derivatives, advantageously pullulan, - a polysaccharide selected from the group consisting of hyaluronic acid, one of its salts or derivatives, alginic acid, one of its salts or derivatives, and a mixture of these - lactic acid, one of its salts or derivatives, - succinic acid, one of its salts or derivatives and - sucrose, one of its salts or derivatives.

2. Combination according to claim 1, characterized in that the polysaccharide is propylene glycol alginate, sodium hyaluronate and / or mixtures thereof.

3. Combination according to any one of claims 1 or 2, characterized in that the weight ratio of pullulan, or derivatives and polysaccharide is within the range of 1 / 0.002 and 1 / 200.

4. A combination according to any one of claims 1 to 3 comprising: - pullulan or one of its derivatives, advantageously pullulan, - hyaluronic acid, one of its salts or derivatives, advantageously sodium hyaluronate, - of alginic acid, one of its salts or derivatives, advantageously of propylene glycol alginate, - of lactic acid, one of its salts or derivatives, advantageously of lactic acid, - succinic acid, one of its salts or derivatives, advantageously succinic acid and - sucrose, one of its salts or derivatives, advantageously sucrose.

5. Combination according to any one of claims 1 to 4, characterized in that the pullulan weight ratio or one of its derivatives, hyaluronic acid or its salt or derivative, alginic acid or its salt or derivative, lactic acid or its salt or derivative, succinic acid or its salt or derivative and sucrose or its salt or derivative is found in the range l / l / l / l / l / l to 1 / 10 / 10 / 300 / 100 / 300, and even more preferably in the range 1 / 1 / 1 / 10 / 5 / 10 to 1 / 2 / 5 / 100 / 50 / 100, even more preferably in the range 1 / 1 / 1 / 20 / 5 / 20 to 1 / 1 / 2 / 30 / 10 / 35, advantageously a ratio of 1 / 1 / 2 / 24 / 8 / 30.

6. Mixture of cosmetic or pharmaceutical ingredients intended to be incorporated into a cosmetic or pharmaceutical composition, said mixture comprising the combination according to any one of claims 1 to 5 and a suitable cosmetic or pharmaceutical vehicle.

7. Mixture of cosmetic or pharmaceutical ingredients according to claim 6, characterized in that it comprises the combination in a content of between 0.001 and 30% by weight of dry matter relative to the total weight of the mixture of ingredients, advantageously between 0.1 and 20% by weight, preferably in association with glycerin and / or xanthan gum and / or pentylene glycol and / or caprylyl glycol.

8. Cosmetic or pharmaceutical composition intended for topical administration comprising the combination according to any one of claims 1 to 5 or the mixture of cosmetic or pharmaceutical ingredients according to any one of claims 6 or 7 and a suitable cosmetic or pharmaceutical vehicle.

9. Composition according to claim 8, characterized in that it comprises the combination in a content of between 0.0001% and 20% by weight of dry matter relative to the total weight of the composition, advantageously between 0.005% and 5% by weight.

10. Non-therapeutic cosmetic use of the combination according to any one of claims 1 to 5 or of the mixture of cosmetic ingredients according to any one of claims 6 or 7 or of the cosmetic composition according to any one of claims 8 or 9 to limit and / or reduce the virulence of Cutibacterium acnes on the skin and / or mucous membranes, in particular by at least one of the following mechanisms: - by inhibiting or limiting the adhesion of Cutibacterium denes,' - by inhibiting or limiting the production of Cutibacterium acnes virulence factors such as biofilm.

11. Cosmetic use according to claim 10 to prevent and / or reduce and / or suppress the unsightly and / or unpleasant and / or uncomfortable manifestations due to the virulence of C. acnes, in particular to prevent and / or reduce and / or delay the secretion of sebum and its unsightly and / or unpleasant and / or uncomfortable manifestations, more particularly to prevent and / or reduce and / or delay the formation of blackheads and / or comedogenesis, and / or prevent and / or reduce the visibility of skin pores, and / or maintain and / or improve the homogeneity and / or radiance and / or luminosity of the complexion of the skin and / or mucous membranes, and / or prevent and / or treat the sensation of overheating of the skin and / or mucous membranes, and / or to prevent and / or reduce hair loss and / or to prevent and / or reduce dandruff.

12. A non-therapeutic cosmetic treatment method characterized in that it comprises the application, to at least one affected area of ​​the skin and / or mucous membranes of the face and / or body, of the combination according to any one of claims 1 to 5 or the mixture of cosmetic ingredients according to any one of claims 6 or 7 or the cosmetic composition according to any one of claims 8 or 9, to limit or reduce the virulence of Cutibacterium acnes on the skin and / or mucous membranes, particularly through at least one of the following mechanisms: - by inhibiting or limiting the adhesion of Cutibacterium denes,' - by inhibiting or limiting the production of Cutibacterium acnes virulence factors such as biofilm.

13. Cosmetic treatment method according to claim 12 for preventing and / or reducing unsightly and / or unpleasant and / or uncomfortable manifestations due to the virulence of C. acnes, in particular for preventing and / or reducing and / or delaying sebum secretion and its unsightly and / or unpleasant and / or uncomfortable manifestations, more particularly for preventing and / or reducing and / or delaying the formation of blackheads and / or comedogenesis, and / or reducing the visibility of skin pores, and / or maintaining and / or improving the evenness, radiance and / or luminosity of the skin and / or mucous membrane complexion, and / or preventing and / or treating the sensation of overheating of the skin and / or mucous membranes, and / or for preventing and / or reducing hair loss, and / or for preventing and / or reducing dandruff 14. A cosmetic treatment method according to any one of claims 12 or 13, characterized in that the relevant area of ​​the skin and / or mucous membranes of the face or body is selected from all or part of the human body, in particular the forehead, cheeks, chin, nose, the so-called "T-shaped" area (forehead, nose and chin), neck and lip contour, scalp, shoulders, arms, back, torso, décolleté, ocular mucosa, nasal mucosa, oral mucosa, in particular the labial and / or gingival mucosa, excessively cleansed areas and / or areas of skin or mucous membrane whose skin barrier has been impaired, for example, due to mechanical, chemical or biological action, such as sunburn, shaving, the use of unsuitable cleansing products or too astringent, due to pollution, the use of antibiotics, or allergens.

15. Combination according to any one of claims 1 to 5 or mixture of pharmaceutical ingredients according to any one of claims 6 or 7 or pharmaceutical composition, in particular dermatological, according to any one of claims 8 or 9 for its use as a pharmaceutical active, in particular dermatological, in particular to prevent and / or treat pathologies due to the virulence of C. acnes, advantageously involving an increase in biofilm secretion and / or an increase in the adhesion of C. acnes.

16. Combination or mixture of pharmaceutical ingredients or pharmaceutical composition for its use according to claim 15, characterized in that the pathologies are chosen from the group consisting of bacterial infections of the skin and / or mucous membranes, pustules, papules, boils, folliculitis, abscesses, acne, in particular superinfected, wounds in particular superinfected, inflammation of the skin and / or mucous membranes, and / or in the prevention of scarring, in particular pigment spots and / or acne scars.

17. Combination according to any one of claims 1 to 5 or mixture of pharmaceutical ingredients according to any one of claims 6 or 7 or pharmaceutical composition according to any one of claims 8 or 9 for its use in preventing and / or treating acne, in particular superinfected acne, and / or acne scars.